A Registry Study on Rimegepant for the Treatment of Migraine Participants in Guangdong-Hong Kong-Macao Greater Bay Area

Inclusion Criteria:

• Participants with headaches that meet the diagnostic criteria for migraines accordingto the International Classification of Headache Disorders, 3rd edition (ICHD-3), withor without aura.
• Patients prescribed rimegepant by the attending physician for the treatment ofmigraines.
• Signed informed consent form.
• Age greater than 18 years.
• Not concurrently participating in other interventional clinical studies.

Exclusion Criteria:

• Patients diagnosed with secondary headaches.
• Patients with severe visual, auditory, language, intellectual, memory, consciousnessimpairments or other conditions that prevent them from completing the questionnaireand follow-up.
• Pregnant or lactating female patients.
• Patients deemed by the investigator as unsuitable for participation in the study orunable to complete the 4-week follow-up.
• Patients with a known history of hypersensitivity reactions to rimegepant or itscomponents.
• Evidence in the medical history suggesting the presence of uncontrolled or unstablecardiovascular diseases (such as ischemic heart disease, coronary artery vasospasm, orcerebrovascular ischemia), or a history of myocardial infarction, acute coronarysyndrome, percutaneous coronary intervention, cardiac surgery, stroke, or transientischemic attack within the past 6 months before the screening visit.